The merger is complete and the stock will be delisted. Traders holding APGE shares should have already tendered them for the $135.11 cash consideration. There is no further trading opportunity in APGE; any remaining positions should be settled through the merger consideration process.
APGE drugs
APGE drug pipeline →Price Chart
How similar events traded
Executive Summary
Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion. Shareholders received $135.11 per share in cash, and the company's stock will be delisted from Nasdaq effective September 4, 2026. This 25-NSE filing is the formal notification by Nasdaq of the removal from listing and registration of Apogee's common stock, confirming the completion of the merger and the end of public trading in APGE shares.
Key Facts
- Apogee Therapeutics has been acquired by AbbVie in a completed all-cash merger valued at approximately $10.9 billion.
- Shareholders received $135.11 per share in cash.
- The company's stock will be delisted from Nasdaq effective September 4, 2026.
- This 25-NSE filing is the formal notification by Nasdaq of the removal from listing and registration of Apogee's common stock.
- The filing confirms the consummation of the previously announced merger, resulting in a change of control and the termination of all pre-merger equity plans.
Financial Impact
All-cash merger valued at approximately $10.9 billion, with shareholders receiving $135.11 per share.
Risk Factors
- No further trading opportunity in APGE shares; delisting is effective immediately.
- Any remaining shareholders who have not tendered shares may face delays or additional steps to receive the merger consideration.
- The merger consideration is fixed at $135.11 per share; there is no upside beyond this amount.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (Primary) | 0001354457-26-000853 |
| Document: 0001354457-26-000853-index-headers.html | 0001354457-26-000853 |
| Document: 0001354457-26-000853-index.html | 0001354457-26-000853 |
| Document: 0001354457-26-000853.txt | 0001354457-26-000853 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Viewing Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers